Abstract: The use of L(-)SddC [beta-L-2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC)] for the treatment of
Herpes B virus (HBV) infection is hindered by the emergence of drug-resistance associated with the
L526M,
L550V, and
L526M/
M550V mutations of the viral DNA
polymerase (DP).